A second study participant has died possibly as a result of the experimental antibody drug, lecanemab, meant to treat Alzheimer’s, Science reported Nov. 27.
Read the full post on Becker's Hospital Review - Healthcare News
Second study participant dies during Eisai’s Alzheimer’s drug trial
